Feed ALT
AL

Altimmune, Inc.

ALT · NASDAQ

$3.30 +0.92% (+$0.03)
1M +10.00%
Market Cap $641.8M
P/E Ratio -
Div. Yield -
ROE 31.41%
Piotroski F-Score Weak
2/9
Valuation
50 /100
Fair
P/B 1.35x
P/S 20,702.10x
P/FFO N/A
Growth
60 /100
Stable
Book val. growth 6.67%
FCF growth N/A
EPS growth N/A
Profitability
0 /100
Weak
Op. margin 323,306.00%
Gross margin 48,306.50%
FCF margin 246,974.00%
Quality
0 /100
Poor
ROA 17.40%
ROIC 19.47%
Asset turnover 0.00x
Debt
69 /100
Low
Int. coverage -26.22x
Debt/Equity 0.08x
Current ratio 26.78x
Stability
31 /100
Unstable
EPS volatility 8.66%
Beta 0.18x
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ALT
Online

About the company

Altimmune, Inc. (ALT) is a biotechnology company focused on the development of immunotherapies and therapeutic products. The company specializes in the development of vaccines and therapeutics aimed at boosting the immune system and combating various infectious diseases. Their research spans areas such as respiratory diseases, hepatitis B, and other health challenges. Altimmune strives to innovate in the field of immunotherapy and introduce new treatment possibilities. The company leverages modern technologies and scientific research to achieve its goals. Investors interested in the biotechnology sector and healthcare innovations might see potential in Altimmune, Inc. (ALT) shares for growth in this dynamic field.

Sector

Healthcare

Industry

Biotechnology

CEO

Jerome Benedict Durso

Employees

57

Headquarters

Gaithersburg

Upcoming events

05 NOV

Earnings

Upcoming earnings report

51d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.